BACKGROUND: Opioid analgesic use and disorders have dramatically increased among the general American population and those receiving methadone maintenance treatment (MMT). Most research among MMT patients focuses on opioid analgesics misuse or disorders; few studies focus on MMT patients prescribed opioid analgesics. We describe demographic, clinical, and substance use characteristics of MMT patients prescribed opioid analgesics and compare them with MMT patients not prescribed opioid analgesics. METHODS: We conducted a cross-sectional secondary data analysis using screening interviews from a parent study. From 2012 to 2015, we recruited adults from 3 MMT Bronx clinics. Questionnaire data included patterns of opioid analgesic use, substance use, comorbid illnesses, and demographic characteristics. Our main dependent variable was patients' report of currently taking prescribed opioid analgesics. To compare characteristics between MMT patients prescribed and not prescribed opioid analgesics, we conducted chi-square tests, t tests, and Mann-Whitney U tests. RESULTS: Of 611 MMT patients, most reported chronic pain (62.0%), hepatitis C virus (HCV) infection (52.1%), and current use of illicit substances (64.2%). Of the 29.8% who reported currently taking prescribed opioid analgesics, most misused their opioid analgesics (57.5%). Patients prescribed (versus not prescribed) opioid analgesics were more likely to report human immunodeficiency virus (HIV) infection (adjusted odds ratio [aOR] = 1.6, 95% confidence interval [CI]: 1.1-2.3) and chronic pain (aOR = 7.6, 95% CI: 4.6-12.6). CONCLUSION: Among MMT patients primarily in 3 Bronx clinics, nearly one third reported taking prescribed opioid analgesics. Compared with patients not prescribed opioid analgesics, those prescribed opioid analgesics were more likely to report chronic pain and HIV infection. However, between these patients, there was no difference in illicit substance use. These findings highlight the complexity of addressing chronic pain in MMT patients.
BACKGROUND: Opioid analgesic use and disorders have dramatically increased among the general American population and those receiving methadone maintenance treatment (MMT). Most research among MMTpatients focuses on opioid analgesics misuse or disorders; few studies focus on MMTpatients prescribed opioid analgesics. We describe demographic, clinical, and substance use characteristics of MMTpatients prescribed opioid analgesics and compare them with MMTpatients not prescribed opioid analgesics. METHODS: We conducted a cross-sectional secondary data analysis using screening interviews from a parent study. From 2012 to 2015, we recruited adults from 3 MMT Bronx clinics. Questionnaire data included patterns of opioid analgesic use, substance use, comorbid illnesses, and demographic characteristics. Our main dependent variable was patients' report of currently taking prescribed opioid analgesics. To compare characteristics between MMTpatients prescribed and not prescribed opioid analgesics, we conducted chi-square tests, t tests, and Mann-Whitney U tests. RESULTS: Of 611 MMTpatients, most reported chronic pain (62.0%), hepatitis C virus (HCV) infection (52.1%), and current use of illicit substances (64.2%). Of the 29.8% who reported currently taking prescribed opioid analgesics, most misused their opioid analgesics (57.5%). Patients prescribed (versus not prescribed) opioid analgesics were more likely to report human immunodeficiency virus (HIV) infection (adjusted odds ratio [aOR] = 1.6, 95% confidence interval [CI]: 1.1-2.3) and chronic pain (aOR = 7.6, 95% CI: 4.6-12.6). CONCLUSION: Among MMTpatients primarily in 3 Bronx clinics, nearly one third reported taking prescribed opioid analgesics. Compared with patients not prescribed opioid analgesics, those prescribed opioid analgesics were more likely to report chronic pain and HIV infection. However, between these patients, there was no difference in illicit substance use. These findings highlight the complexity of addressing chronic pain in MMTpatients.
Authors: Paul Kurdyak; Tara Gomes; Zhan Yao; Muhammad M Mamdani; Chelsea Hellings; Benedikt Fischer; Jürgen Rehm; Ahmed M Bayoumi; David N Juurlink Journal: Addiction Date: 2012-01-18 Impact factor: 6.526
Authors: Andrew Rosenblum; Mark Parrino; Sidney H Schnoll; Chunki Fong; Carleen Maxwell; Charles M Cleland; Stephen Magura; J David Haddox Journal: Drug Alcohol Depend Date: 2007-03-26 Impact factor: 4.492
Authors: Joseph O Merrill; Lorna A Rhodes; Richard A Deyo; G Alan Marlatt; Katharine A Bradley Journal: J Gen Intern Med Date: 2002-05 Impact factor: 5.128
Authors: Gregory M Lucas; Amina Chaudhry; Jeffrey Hsu; Tanita Woodson; Bryan Lau; Yngvild Olsen; Jeanne C Keruly; David A Fiellin; Ruth Finkelstein; Patricia Barditch-Crovo; Katie Cook; Richard D Moore Journal: Ann Intern Med Date: 2010-06-01 Impact factor: 25.391
Authors: Alexander Y Walley; Danielle Farrar; Debbie M Cheng; Daniel P Alford; Jeffrey H Samet Journal: J Gen Intern Med Date: 2009-07-04 Impact factor: 5.128
Authors: Andrew Rosenblum; Herman Joseph; Chunki Fong; Steven Kipnis; Charles Cleland; Russell K Portenoy Journal: JAMA Date: 2003-05-14 Impact factor: 56.272
Authors: Celeste M Caviness; Bradley J Anderson; Marcel A de Dios; Megan Kurth; Michael Stein Journal: Drug Alcohol Depend Date: 2012-07-31 Impact factor: 4.492
Authors: Robin M Nance; J A Chris Delaney; Carol E Golin; Wendee M Wechsberg; Chinazo Cunningham; Frederick Altice; Katerina Christopoulos; Kevin Knight; Vu Quan; Michael S Gordon; Sandra Springer; Jeremy Young; Paul K Crane; Kenneth H Mayer; Michael J Mugavero; Carlos Del Rio; Richard A Kronmal; Heidi M Crane Journal: AIDS Care Date: 2016-12-02
Authors: Tomorrow D Arnold; Lewei Allison Lin; Brandi P Cotton; William C Bryson; Courtney A Polenick Journal: Subst Use Misuse Date: 2021-03-01 Impact factor: 2.164
Authors: Deepika E Slawek; Julia Arnsten; Nancy Sohler; Chenshu Zhang; Robert Grossberg; Melissa Stein; Chinazo O Cunningham Journal: AIDS Care Date: 2020-08-04
Authors: Jørn Henrik Vold; Svetlana Skurtveit; Christer Aas; Kjell Arne Johansson; Lars Thore Fadnes Journal: BMC Health Serv Res Date: 2020-07-20 Impact factor: 2.655